We develop dendritic cell-targeted LNPs through DC-selective lipid engineering and surface display of glycan, antibody, and single-domain antibody ligands, providing end-to-end support from lipid design and synthesis to formulation, characterization, and immune delivery evaluation.
Dendritic cell-targeted LNPs are engineered to direct nucleic acids, antigens, and immune modulators to dendritic cells (DCs)—the professional antigen-presenting cells that bridge innate sensing and adaptive immunity. A single DC can activate 100–200 naïve T cells, yet conventional ionizable LNPs deliver most of their payload to hepatocytes, leaving antigen-presenting cells with only a marginal share of the dose. DC-targeted formulations address this gap by combining DC-permissive ionizable lipids, tuned PEG-lipid architectures, and surface-displayed ligands—such as mannose, anti-DEC205, or anti-CLEC9A constructs—to shift particle uptake toward DCs, control the targeted DC subset, and shape the resulting Th1/Th2 immune bias.
BOC Sciences provides integrated targeted LNP development, covering DC-selective lipid screening, glycan and antibody ligand synthesis, surface functionalization, payload encapsulation, formulation optimization, and cellular and in vivo immune evaluation. We support customized LNPs for mRNA, siRNA, saRNA, circRNA, miRNA, ASO, CRISPR components, antigen proteins, and antigen–adjuvant co-delivery programs, with the targeting layer selected according to the intended DC subset and immune objective.
Dendritic Cell-Targeted Lipid Nanoparticle IllustrationOur development services combine lipid chemistry, ligand engineering, nanoparticle formulation, and immunological evaluation to address the specific challenges of dendritic cell delivery. Projects can begin with an existing LNP formulation, a candidate targeting ligand, or only a defined immune objective—such as raising a Th1-biased CD8+ T cell response or inducing tolerogenic DC signaling. We customize the development scope according to payload properties, target DC subset, and the intended administration route.
We investigate how ionizable lipid structures and supporting lipid components influence DC association, endosomal handling, and immune organ distribution.
We develop ligand-functionalized LNPs to improve interactions with dendritic cells and selected DC subsets. Ligand identity, attachment chemistry, surface orientation, and display density are evaluated together.
We integrate lipid composition, targeting modifications, and payload properties into a formulation strategy designed for the intended immune application.
We evaluate candidate LNPs at three levels—particle, cell, and organism—so that formulation changes can be interpreted against functional immune delivery rather than uptake alone.
DC-targeted LNPs can be developed through glycan-mediated receptor recognition, subset-specific antibody and single-domain antibody display, or ligand-free particle engineering in which size, PEG density, and surface charge enrich delivery to antigen-presenting cells. BOC Sciences supports ligand design and synthesis, lipid engineering, LNP formulation, and comparative evaluation. The following strategies provide different options for developing DC-targeted delivery systems.
Glycan-functionalized LNPs exploit C-type lectin receptors abundantly expressed on dendritic cells—most commonly the mannose receptor (CD206)—to promote receptor-mediated endocytosis and antigen presentation. BOC Sciences supports glycan ligand synthesis, lipid-anchor conjugation, glycan-density optimization, and LNP functionalization.
Research reference: Mannosylated mRNA-LNPs (STLNPs-Man) achieving approximately four-fold higher DC uptake than benchmark LNPs and comparable antitumor efficacy at one-fifth of the vaccine dose (Angewandte Chemie International Edition, 2024).
Antibody-fragment-functionalized LNPs direct particles to defined DC subsets—particularly type 1 conventional DCs (cDC1)—through receptors such as DEC205, CLEC9A, and XCR1. Because receptor choice influences the quality of the resulting immune response, we treat receptor selection as a design decision rather than a fixed default. BOC Sciences supports ligand selection, scFv and single-domain antibody production, conjugation chemistry, and functionalized LNP development.
Research reference: DEC205-scFv-coated LNPs delivering siRNA to DCs with functional knockdown of CD40, CD80, and CD86 (Molecular Therapy, 2016); CLEC9A-binding single-domain antibody-functionalized LNPs enlarging mRNA-expressing DC populations and improving neoantigen-driven T cell responses (Vaccines, 2026); comparative receptor-targeting analysis showing that CLEC9A, XCR1, and DEC205 engagement produces distinct antibody and CD8+ T cell outcomes (The Journal of Immunology, 2020).
DC enrichment does not always require an active ligand. Particle size, PEG-lipid density, and surface charge determine whether a formulation drains through lymphatics, filters into splenic antigen-presenting cell zones, or adsorbs the endogenous protein corona that routes particles to DCs. BOC Sciences supports formulation-level engineering and comparator design for ligand-free DC enrichment.
Research reference: Stereodefined ionizable lipid H9T6 in a low-PEG, DOPG-containing formulation improving DC transfection and Th1-biased immune output after intramuscular vaccination (ACS Nano, 2026); large low-PEG LNPs achieving mRNA expression in roughly 82% of GFP+ splenic cells identified as DCs (Journal of Controlled Release, 2026).
DC uptake alone does not guarantee payload expression. mRNA that remains in endosomes is degraded rather than translated, so advanced DC-targeted designs combine surface targeting with pH-responsive or fusogenic components that accelerate endosomal release. BOC Sciences supports dual-functional lipid design, surface engineering, and comparative evaluation of targeting-only versus targeting-plus-escape formulations.
Research reference: Ambidextrous LNPs combining mannose-directed DC targeting with pH-responsive endosomal escape, producing enhanced antigen translation and vigorous antitumor immune responses (mRNA cancer vaccine study, 2025).
Share your payload, target DC subset, and immune objective. BOC Sciences can help evaluate feasible receptor and formulation options, synthesize relevant components, and develop a comparative screening strategy.
BOC Sciences develops DC-targeted LNPs for the payload classes most frequently used in dendritic cell delivery and vaccine research. Each payload imposes different requirements on loading strategy, particle stability, and functional readout, and we help connect the DC-targeting layer with payload-specific formulation demands.
| Payload Type | Supported Uses & Dendritic Cell-Targeted LNP Development Considerations | Request Information |
|---|---|---|
| DC-Targeted LNP for mRNA | The core payload for DC vaccine research, supporting neoantigen and model antigen expression, DC maturation, and T cell priming. Development focuses on mRNA integrity, DC-selective transfection, and lymph node versus liver expression ratios, supported by our lipid nanoparticles for mRNA delivery platform. | Inquiry |
| DC-Targeted LNP for saRNA | Self-amplifying RNA supports low-dose vaccine concepts by intracellularly amplifying antigen expression. Development addresses the larger, structured RNA cargo with higher encapsulation demands, fusogenic helper lipid selection, and expression duration readouts in DC models, drawing on our lipid nanoparticles for saRNA delivery capabilities. | Inquiry |
| DC-Targeted LNP for siRNA | Enables functional gene silencing in DCs—for example, knockdown of costimulatory molecules such as CD40, CD80, and CD86 to study immune suppression or tolerance. Development evaluates oligonucleotide encapsulation, DC-selective uptake against macrophage competitors, and knockdown depth, building on our lipid nanoparticles for siRNA delivery experience. | Inquiry |
| DC-Targeted LNP for circRNA | Circular RNA offers durable, cap-independent antigen expression of interest for prolonged antigen presentation studies. Development considers payload integrity, encapsulation behavior, particle stability, and expression duration in DC and lymph node contexts, supported by our lipid nanoparticles for circRNA delivery platform. | Inquiry |
| DC-Targeted LNP for miRNA | Suitable for tuning DC differentiation and immune signaling pathways, including tolerogenic DC phenotypes studied in autoimmune research. Development evaluates miRNA loading, subset-resolved uptake, and pathway-level readouts, drawing on our lipid nanoparticles for miRNA delivery services. | Inquiry |
| DC-Targeted LNP for ASO | Applicable to splice-modifying and knockdown oligonucleotide research in immune cells, where nuclear delivery to DCs remains a major bottleneck. Development focuses on oligonucleotide loading, nuclear accumulation, and uptake comparison across DC subsets, supported by our lipid nanoparticles for ASO delivery services. | Inquiry |
| DC-Targeted LNP for Cas9 mRNA/sgRNA and CRISPR RNP | Enables transient genome-editing studies in DCs and hematopoietic populations, where repeat dosing and short Cas9 exposure are advantageous. We evaluate co-loading of Cas9 mRNA with guide RNA or direct ribonucleoprotein loading, editing readouts in DC models, and particle consistency, building on our lipid nanoparticles for CRISPR RNP delivery capabilities. | Inquiry |
| DC-Targeted LNP for Antigen Protein and Peptide | Supports direct antigen delivery for MHC loading and cross-presentation studies, including model antigens and tumor-derived peptide pools. Formulation work emphasizes mild loading conditions, preserved conformation, and DC uptake, drawing on our lipid nanoparticles for antigen delivery experience. | Inquiry |
| DC-Targeted LNP for Antigen–Adjuvant Co-Delivery | Designed so antigen and adjuvant arrive in the same DC at the same time—critical for TLR agonist-based, CpG-based, and STING-pathway programs. Development evaluates co-encapsulation compatibility, adjuvant distribution between particle compartments, and innate activation readouts, supported by our lipid nanoparticles for co-delivery capabilities. | Inquiry |
| DC-Targeted LNP for Fluorescent and Tracking Labels | Supports labeled particles used to quantify the DC fraction among payload-positive cells, map lymph node versus spleen distribution, and validate whether ligand targeting survives the protein corona, enabled by our tracking-labeled lipid nanoparticles capabilities. | Inquiry |
| DC-Targeted LNP for Custom Payload | Developed for unusual payloads, dual-payload systems, or early feasibility studies. We evaluate payload compatibility, loading sequence, DC-targeting modification route, particle stability, and delivery performance in the agreed DC models. | Inquiry |
Tell us your payload, target DC subset, and administration route, and BOC Sciences will propose a DC-targeting strategy that fits your project.
Projects can begin with an existing LNP formulation, a candidate targeting ligand, or only a delivery objective. We organize the work into four practical stages and refine the plan as formulation and immune-delivery evidence becomes available.

We review the payload class, the intended DC population—cDC1, cDC2, plasmacytoid DC, or migratory tissue DC—the desired immune outcome such as CD8+ T cell priming or tolerogenic signaling, baseline formulation if available, and the target administration route. These inputs define the receptor candidates, comparator models, and the screening plan.

We propose candidate ionizable lipids, helper lipid and cholesterol balances, and PEG-lipid architectures, then select the targeting layer—glycan display, antibody-fragment display, or ligand-free size and PEG engineering. Ratios are optimized through structured LNP lipid ratio optimization services, and each design includes matched non-targeted control LNPs so targeting effects can be attributed unambiguously.

Candidates are prepared under controlled mixing conditions and compared for particle size, PDI, zeta potential, ligand density, and payload retention. We adjust composition, ligand input, purification, and buffer exchange, then advance only candidates that meet agreed particle-attribute thresholds and demonstrate preserved ligand accessibility after serum exposure.

Selected candidates are evaluated in DC models using uptake imaging, flow cytometry with subset markers, and payload-specific endpoints such as reporter expression, maturation phenotype, or gene knockdown. In vivo studies then compare lymph node and spleen delivery against hepatic and macrophage-associated accumulation. In one recent mRNA neoantigen project, we screened twelve ionizable lipid candidates alongside three targeting architectures—mannosylated DSPE-PEG, anti-CLEC9A single-domain antibody display, and a ligand-free low-PEG design—against a common mRNA payload, and the single-domain antibody-functionalized formulation advanced with the highest DC fraction among payload-positive cells together with the strongest CD8+ T cell activation, while the low-PEG design was retained as a simpler manufacturing backup.
A DC-targeted LNP may look well characterized chemically yet still deliver mostly to hepatocytes, macrophages, or the wrong DC subset—and uptake itself does not guarantee antigen presentation. We investigate formulation and immunological factors together and use matched comparison studies to identify the step limiting performance.
✔ Low Dendritic Cell Uptake by LNPs and Off-Target Phagocyte Capture
Conventional LNPs follow ApoE and LDL-receptor pathways into hepatocytes, while splenic macrophages and Kupffer cells capture much of the remainder before DCs see any dose. We compare ionizable lipid structures, PEG densities, helper lipid identities, and targeting ligands to shift uptake, and we quantify the DC fraction among payload-positive cells for every candidate rather than reporting total expression alone.
✔ Limited LNP Selectivity Across Dendritic Cell Subsets
Receptors widely used for DC targeting—such as the mannose receptor—are also expressed on macrophages and endothelial cells, and different receptors on the same cDC1 population produce different Th1/Th2 polarization and antibody isotype outcomes. We build subset-resolved flow cytometry readouts into each screening round, so receptor selection is made against measured DC subset engagement and immune bias data instead of receptor-list assumptions.
✔ Insufficient Endosomal Escape and Payload Expression from LNPs
DCs are notoriously difficult transfection targets, and internalized mRNA is frequently degraded in the endolysosomal pathway before translation. We measure ligand exposure alongside particle stability, compare intracellular localization with functional readouts, and apply LNP endosomal escape evaluation to identify post-uptake limitations before reformulating.
✔ Uneven LNP Delivery to Lymph Nodes and Target Tissues
Lymphatic drainage after local injection and spleen filtration after intravenous administration each impose size- and surface-dependent filters, and the protein corona can redirect particles away from their intended receptor. We use labeled particles and compartment-aware readouts to map where payload expression actually occurs, then adjust particle size, PEG density, charge, and route-compatible design variables to reduce variability across the intended DC populations.
Tell us about your current lipid composition, targeting strategy, payload, and evaluation results. BOC Sciences can help investigate the limiting formulation parameters and establish a focused optimization plan.
Dendritic cell-targeted LNPs provide a versatile approach for delivering antigen-encoding RNA, immunomodulatory oligonucleotides, and other research payloads to antigen-presenting cells. By combining cell-directed delivery with functional intracellular release, these systems can support research into cancer vaccines, antigen presentation, infectious disease immunity, and immune-regulatory gene modulation. BOC Sciences develops customized LNP formulations according to the intended immune response and payload requirements.
Tell us your intended application and development requirements. Drawing on our experience and relevant published research, BOC Sciences can help design, synthesize, formulate, and evaluate DC-targeted LNPs tailored to your project.
We connect ionizable lipid structure, PEG architecture, and receptor choice to DC subset engagement and immune bias, helping teams move beyond liver-tropic default formulations with a defined, data-supported design logic.

Our workflows cover glycan ligands, scFv and VHH constructs, peptide motifs, and ligand-free particle engineering, allowing the targeting layer to be matched to the DC subset and immune objective rather than forced onto a fixed platform.
Particle profiling, subset-resolved DC uptake, endosomal escape assessment, and in vivo lymph node and spleen distribution studies are combined in one program, so formulation changes can be interpreted against both cellular and tissue-level delivery data.
Screening campaigns are organized around parallel candidate comparison with matched non-targeted controls and agreed endpoints, giving teams fast, interpretable feedback on which design variable to adjust in the next iteration.
From ligand selection and lipid synthesis to formulation, characterization, and immune delivery evaluation, the full development chain is handled within one integrated plan, reducing the disconnect between targeting chemistry and particle performance.
Dendritic cell-targeted lipid nanoparticles (DC-targeted LNPs) are lipid-based delivery systems engineered to transport nucleic acids and other functional payloads into dendritic cells (DCs). These nanoparticles can be modified with receptor-binding ligands, such as mannose or antibody-based components, or optimized through lipid composition and particle-size engineering to improve DC uptake. Their applications include antigen expression, immune modulation, and gene silencing research. Unlike conventional LNPs, which may accumulate in the liver or other phagocytic cells, DC-targeted formulations aim to improve delivery to selected antigen-presenting cell populations and support functional intracellular payload release.
DC-targeted LNPs can be engineered through surface functionalization and lipid composition optimization. Mannose-bearing lipids can facilitate recognition by CD206-positive cells, while antibodies or engineered protein binders directed toward CLEC9A and DEC205 can support receptor-mediated delivery to selected DC populations. Particle size, PEG-lipid content, and ionizable lipid structure can also be adjusted to influence cellular uptake and tissue distribution. BOC Sciences supports these approaches through customized lipid design, targeting ligand synthesis, surface conjugation, LNP formulation, and comparative cellular evaluation. The optimal design depends on receptor expression, target DC subsets, payload properties, and administration route.
Several receptors can be explored for dendritic cell-targeted LNP development. CD206, also known as the mannose receptor, recognizes mannose-containing structures and can facilitate uptake by selected antigen-presenting cells, although it is also expressed by macrophages. CLEC9A is particularly relevant to cDC1 targeting and antigen cross-presentation, whereas DEC205 is an endocytic receptor investigated for DC-directed antigen and siRNA delivery. Receptor selection should consider cell-subset expression, species compatibility, and ligand accessibility. BOC Sciences can help evaluate receptor-binding components and compare their uptake profiles across DC populations and other immune-cell types.
DC-targeted LNPs can deliver several types of research payloads, particularly mRNA and siRNA. Antigen-encoding mRNA can support intracellular expression of tumor-associated antigens, neoantigens, or viral antigens for antigen-presentation research. siRNA can be used to investigate gene silencing involving costimulatory or immune-regulatory pathways. Co-delivery strategies may combine antigen-encoding mRNA with siRNA or immunostimulatory oligonucleotides to investigate coordinated antigen expression and immune modulation. BOC Sciences develops payload-compatible formulations by optimizing encapsulation conditions, lipid-to-payload ratios, particle composition, and intracellular release according to the intended DC application.
Functional delivery evaluation combines nanoparticle characterization, cell-specific uptake analysis, intracellular trafficking, and biological readouts. Initial characterization includes particle size, polydispersity index, zeta potential, morphology, and encapsulation efficiency. Cellular studies compare LNP uptake across selected DC subsets, including cDC1 and cDC2, with macrophages and other immune cells serving as relevant comparators. Further evaluation can include endosomal escape, reporter expression, target-gene knockdown, DC maturation markers, cytokine production, and antigen presentation. For selected projects, studies can assess lymph node and spleen distribution, DC localization, and off-target organ accumulation to determine whether particle uptake translates into functional delivery.